Because of their capacity to sustain therapeutic drug concentrations for extended periods of time, reduce dosing frequency, lessen fluctuations in plasma drug concentration, and potentially increase patient compliance, controlled release matrix tablets have been thoroughly studied as oral drug delivery methods. However, because drug release behaviour is influenced concurrently by formulation composition, polymer concentration/grade, drug characteristics, tablet porosity, compression force, and manufacturing variables, developing a robust matrix tablet is difficult. A methodical framework for understanding these relationships and creating a formulation with preset quality criteria is provided by the Quality by Design (QbD) methodology.

The design and optimisation of a matrix-type controlled release tablet employing a QbD-based development approach was the main goal of the current work. The method included defining the Quality Target Product Profile (QTPP), identifying Critical Quality Attributes (CQAs), assessing risk, choosing critical material attributes (CMAs) and critical process parameters (CPPs), designing experiments (DoE), statistical analysis, optimisation, and formulation verification. With hydroxypropyl methylcellulose (HPMC) and microcrystalline cellulose (MCC) as the primary formulation variables, a hydrophilic matrix system was selected as the model platform. Polymer concentration and polymer viscosity grade were the primary formulation elements taken into account. Drug release characteristics at specific time points and tablet mechanical features were significant responses.

The impact of HPMC content and polymer viscosity grade on cumulative drug release at 2, 8, and 12 hours, tablet hardness, and friability were assessed using an illustrative 3 2 factorial experimental design. Because of the increased gel layer development and diffusion resistance, the model findings demonstrated that higher polymer concentration and viscosity generally reduced the drug release rate. In order to accomplish controlled release without sacrificing the tablets' ability to be manufactured, a potential formulation space was found. With acceptable hardness and friability, the optimised formulation demonstrated an approximate cumulative release of roughly 20% at 2 hours, 63% at 8 hours, and 89% at 12 hours. The improved formulation followed an anomalous or non-Fickian transport, suggesting a combination of diffusion and matrix erosion mechanisms, according to release-kinetic evaluation.

The study demonstrates how QbD can turn the trial-and-error approach of developing controlled-release tablets into a risk-based, scientifically supported development program. The method provides a logical foundation for matrix-type controlled-release dosage form formulation optimisation, design space establishment, control strategy creation, and lifecycle management.